Literature DB >> 9703927

Low-frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder.

G Olderøy1, L Daehlin, D Ogreid.   

Abstract

UNLABELLED: BACKGROUND, PATIENTS AND METHODS: The objective was to study the frequency of mutations of Ha-ras and Ki-ras oncogenes in bladder tumours. Transitional cell tumours of the bladder from 55 patients were subjected to analyses of Ha-ras and Ki-ras oncogenes using a variety of techniques including sequencing to detect mutations.
RESULTS: Two tumours (4%) exhibited mutation of the Ki-ras oncogene, both tumours were fast growing and invasive. We did not detect Ha-ras mutation in any of the samples. Nineteen tumours (35%) with established invasion of the detrusor muscle, did not reveal any mutation.
CONCLUSION: Analyses of ras oncogenes seem to be of limited value for the biological assessment of transitional cell carcinomas.

Entities:  

Mesh:

Year:  1998        PMID: 9703927

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Depression and cancer risk: 24 years of follow-up of the Baltimore Epidemiologic Catchment Area sample.

Authors:  Alden L Gross; Joseph J Gallo; William W Eaton
Journal:  Cancer Causes Control       Date:  2009-11-03       Impact factor: 2.506

2.  Gene expression profiling of chemically induced rat bladder tumors.

Authors:  Ruisheng Yao; Yijun Yi; Clinton J Grubbs; Ronald A Lubet; Ming You
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

Review 3.  Behavioral genetics of the depression/cancer correlation: a look at the Ras oncogene family and the 'cerebral diabetes paradigm'.

Authors:  Janet K Brewer
Journal:  J Mol Neurosci       Date:  2008-06-18       Impact factor: 3.444

4.  K-RAS mutation in transitional cell carcinoma of urinary bladder.

Authors:  S Ayan; G Gokce; H Kilicarslan; O Ozdemir; E Yildiz; E Y Gultekin
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

5.  The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.

Authors:  Slah Ouerhani; Karim Bougatef; Ismail Soltani; Amel Ben Ammar Elgaaied; Salem Abbes; Samia Menif
Journal:  Mol Biol Rep       Date:  2013-05-03       Impact factor: 2.316

6.  Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamine.

Authors:  Ruisheng Yao; William J Lemon; Yian Wang; Clinton J Grubbs; Ronald A Lubet; Ming You
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

7.  Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis.

Authors:  I Ahmad; R Patel; Y Liu; L B Singh; M M Taketo; X-R Wu; H Y Leung; O J Sansom
Journal:  Cell Death Dis       Date:  2011-03-03       Impact factor: 8.469

8.  A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

Authors:  Gottfrid Sjödahl; Martin Lauss; Sigurdur Gudjonsson; Fredrik Liedberg; Christer Halldén; Gunilla Chebil; Wiking Månsson; Mattias Höglund; David Lindgren
Journal:  PLoS One       Date:  2011-04-14       Impact factor: 3.240

9.  Inhibitory effect of flavonoids on mutant H-Rasp protein.

Authors:  Tariq A Masoodi; Adel H Alhamdanz
Journal:  Bioinformation       Date:  2010-06-15

10.  K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder.

Authors:  Imran Ahmad; Lukram Babloo Singh; Mona Foth; Carol-Ann Morris; Makoto Mark Taketo; Xue-Ru Wu; Hing Y Leung; Owen J Sansom; Tomoko Iwata
Journal:  Dis Model Mech       Date:  2011-04-18       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.